Indacterol/glycopyrronium/mometasone furoate (Enerzair®). HTA ID: 20023

Assessment Status Rapid Review Complete
HTA ID 20023
Drug Indacterol/glycopyrronium/mometasone furoate
Brand Enerzair®
Indication As a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting β2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Assessment Process
Rapid review commissioned 13/05/2020
Rapid review completed 10/06/2020
Rapid review outcome A full HTA is not recommended. The NCPE recommends that indacterol/glycopyrronium/mometasone furoate (Enerzair®) be considered for reimbursement*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement; November 2020